Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
07/2003
07/10/2003WO2003056012A1 A system for stable expression of sirnas in mammalian cells
07/10/2003WO2003055980A2 Il-17 like molecules and uses thereof
07/10/2003WO2003055918A1 Negatively charged polysaccharide derivable from aloe vera
07/10/2003WO2003055916A2 Adiponectin fragments and conjugates
07/10/2003WO2003055915A2 Human netrin receptor and uses thereof
07/10/2003WO2003055913A2 Secreted protein
07/10/2003WO2003055912A2 Secreted proteins
07/10/2003WO2003055911A2 Cystine-knot fold protein
07/10/2003WO2003055910A1 Beta-amyloid binding factors and inhibitors thereof
07/10/2003WO2003055886A1 Amorphous substance of tricyclic triazolobenzazepine derivative
07/10/2003WO2003055885A1 Novel crystalline tricyclic triazolobenzazepine derivative
07/10/2003WO2003055884A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
07/10/2003WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
07/10/2003WO2003055876A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
07/10/2003WO2003055875A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055874A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055868A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
07/10/2003WO2003055863A1 Novel alkansulfonamides as endothelin antagonists
07/10/2003WO2003055851A1 Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
07/10/2003WO2003055848A2 Urea derivatives as vr1- antagonists
07/10/2003WO2003055847A1 Carboxylic acid derivative
07/10/2003WO2003055843A1 Agaricoglycerides and analogs
07/10/2003WO2003055536A1 A wound care device
07/10/2003WO2003055525A1 Acid-containing preparations
07/10/2003WO2003055501A1 The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
07/10/2003WO2003055497A1 Buffalo milk gangliosides
07/10/2003WO2003055484A1 Urea derivatives
07/10/2003WO2003055462A2 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof
07/10/2003WO2003055456A1 Stable surfactant compositions for suspending components
07/10/2003WO2003055447A2 Heterocyclic acridone inhibitors of impdh enzyme
07/10/2003WO2003055445A2 Compositions and methods for enhancing corticosteriod delivery
07/10/2003WO2003055442A2 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
07/10/2003WO2003055440A2 Compositions and methods for the treatement of immune related diseases
07/10/2003WO2003043905A3 Pharmaceutical product with an adsorbent
07/10/2003WO2003015698A3 Application of lipid vehicles and use for drug delivery
07/10/2003WO2003011227A3 Taste masking composition
07/10/2003WO2003008452A3 Bispecific monoclonal antibodies to il-12 and il-18 receptors
07/10/2003WO2003004511A3 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
07/10/2003WO2002100354A8 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
07/10/2003WO2002083060A3 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
07/10/2003WO2002063008A3 Intracellular signaling molecules
07/10/2003WO2002059267A3 Constitutively desensitized g protein-coupled receptors
07/10/2003WO2002046409A3 Proteins and nucleic acids encoding same
07/10/2003WO2002013845A3 Inflammation related g-protein coupled receptor
07/10/2003WO2002000730A9 Pd-l2 molecules: novel pd-1 ligands and uses therefor
07/10/2003WO2001098269A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
07/10/2003WO2001089549A3 Therapeutic uses of il-1 receptor antagonist
07/10/2003US20030131370 Disruption of the glutathione S-transferase-Omega-1 gene
07/10/2003US20030130517 Useful as antiinflammatory drugs, particularly as remedies for rheumatoid arthritis
07/10/2003US20030130515 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
07/10/2003US20030130508 3,5-bis(trifluoromethyl)phenylmethylene-substituted derivatives of nicotamide or pyridinylaminocarbonyl compounds; used to treat disorders of the central nervous system such as anxiety, depression and psychosis.
07/10/2003US20030130355 Serotonin/noradrenaline reuptake inhibitors (N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethylamine; dietetics; side effects reduction
07/10/2003US20030130337 Indole derivatives as anti-inflammatory agents
07/10/2003US20030130335 Protein tyrosine phosphatases inhibitors
07/10/2003US20030130333 Combination product and methods of use
07/10/2003US20030130325 Substituted tryptophan derivatives
07/10/2003US20030130319 Aminopyrrole compounds
07/10/2003US20030130314 Administering 4-amido-piperidineo derivatives to patients already under the background influence of an opioid agonist
07/10/2003US20030130309 Antiinflammatory agents; rheumatic diseases
07/10/2003US20030130297 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
07/10/2003US20030130292 Immunosuppressants; autoimmune disease; skin disorders; Crohn's disease; antidiabetic agents; anticancer agents; antiarthritic agents
07/10/2003US20030130286 Antiproliferative agents; anticancer agents; central nervous system disorders; antiarthritic agents
07/10/2003US20030130285 Controlling cell differentiation, cell proliferation
07/10/2003US20030130283 CRF receptor antagonists and methods relating thereto
07/10/2003US20030130279 Hyperglycemic agents; dietetics; cardiovascular disorders; immunology modulation; osteoporosis; cognition activators
07/10/2003US20030130277 Pyrazoloquinolinone derivatives as protein kinase C inhibitors
07/10/2003US20030130273 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
07/10/2003US20030130271 1,3-Diheterocyclic metalloprotease inhibitors
07/10/2003US20030130268 Mixture containing water soluble polymer and surfactant; antiinflammatory agents, antiulcer agents, Crohn's disease
07/10/2003US20030130261 Central nervous system disorders; psychological disorders; inflammatory bowel disorders
07/10/2003US20030130260 Aryl fused azapolycyclic compounds
07/10/2003US20030130254 Respiratory system disorders; antihistamines; antiarthritic agents
07/10/2003US20030130247 Compositions and methods for enhancing corticosteroid delivery
07/10/2003US20030130238 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
07/10/2003US20030130236 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
07/10/2003US20030130235 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
07/10/2003US20030130232 Amidine derivatives, the preparation and use thereof as medicaments with LTB4 antagonistic effect
07/10/2003US20030130225 Urogenital disorders; concurrent administering fluconazole by mouth and topical applying fungicide in situ
07/10/2003US20030130218 Methods of stimulating phagocytosis
07/10/2003US20030130209 Method of treatment of myocardial infarction
07/10/2003US20030130201 Mixture with ascorbic acid, proline and lysine
07/10/2003US20030130200 Tripeptide or tetrapeptide
07/10/2003US20030130182 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/10/2003US20030130176 Spary drying dispersion; antiinflammatory agents; antihistamines; lung diseases
07/10/2003US20030130168 Reverse-turn mimetics and methods relating thereto
07/10/2003US20030129706 Fhm, a novel member of the TNF ligand supergene family
07/10/2003US20030129702 DNA encoding galanin GALR2 receptors and uses thereof
07/10/2003US20030129678 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
07/10/2003US20030129645 Can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity
07/10/2003US20030129606 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
07/10/2003US20030129596 Chemical compounds
07/10/2003US20030129531 Positive-working photoimageable bottom antireflective coating
07/10/2003US20030129242 Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
07/10/2003US20030129235 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
07/10/2003US20030129188 Peptide mimetics; catalytic antibodies such as aldolase, beta-lactamase, esterase, or amidase; for treatment of angiogenesis, bone metabolism disorders, inflammation, or cell growth disorders
07/10/2003US20030129187 Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
07/10/2003US20030129181 Hydrolases modified by polyoxyethylene glycol for induction of high plasmatic levels of free tumor necrosis factor
07/10/2003US20030129150 Cosmetic preparations containing plant extracts
07/10/2003US20030129129 Prevention, therapy disease; forming tritiated water; calibration
07/10/2003CA2482392A1 Carboxylic acid derivative
1 ... 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 ... 1272